Peter Minetti
General Counsel bei Fujirebio Diagnostics, Inc.
Profil
Peter Minetti is Vice President of Quality and Regulatory Compliance for Fujirebio Diagnostics, Inc. Prior to joining Fujirebio Diagnostics he was Manager of Quality Assurance, Quality Control and Regulatory Affairs for Biopool International and Organon Teknika Corp.
Mr. Minetti received a BS degree from City College.
Aktive Positionen von Peter Minetti
| Unternehmen | Position | Beginn |
|---|---|---|
Fujirebio Diagnostics, Inc.
 Fujirebio Diagnostics, Inc. Medical SpecialtiesHealth Technology Fujirebio Diagnostics, Inc. develops, manufactures and commercializes in-vitro diagnostic products. Its products include oncology RIA and EIA kits, veterinary products and research kits. The company was founded in 1965 and is headquartered in Malvern, PA | General Counsel | - |
Ehemalige bekannte Positionen von Peter Minetti
| Unternehmen | Position | Ende |
|---|---|---|
Organon Teknika Corp. LLC
 Organon Teknika Corp. LLC Financial ConglomeratesFinance Part of Merck & Co., Inc., Organon Teknika Corp. LLC is an American company led by the management of PerImmune. | General Counsel | - |
Ausbildung von Peter Minetti
| City University of New York | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Fujirebio Diagnostics, Inc.
Fujirebio Diagnostics, Inc. Medical SpecialtiesHealth Technology Fujirebio Diagnostics, Inc. develops, manufactures and commercializes in-vitro diagnostic products. Its products include oncology RIA and EIA kits, veterinary products and research kits. The company was founded in 1965 and is headquartered in Malvern, PA | Health Technology |
Organon Teknika Corp. LLC
Organon Teknika Corp. LLC Financial ConglomeratesFinance Part of Merck & Co., Inc., Organon Teknika Corp. LLC is an American company led by the management of PerImmune. | Finance |
